Final phase 3 MYR301 results in 150 patients with chronic hepatitis D: bulevirtide virologic response at end of treatment was 73-92% across groups, falling to 30-33% 96 weeks after stopping; post-treatment hepatic SAEs in 14%.
RCTn = 150
Wedemeyer et al. 144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and post-treatment results from a phase III randomized trial